Night curfew in Delhi from today over rising coronavirus cases

Night curfew will be imposed in Delhi from 11 pm on Monday, restricting movement of individuals except those in exempted categories, due to rising COVID-19 cases and the threat posed by Omicron



Night curfew will be imposed in Delhi from 11 pm on Monday, restricting movement of individuals except those in exempted categories, due to rising COVID-19 cases and the threat posed by Omicron, according to a DDMA order.

The night curfew will be in place from 11 pm to 5 am till further orders, the Delhi Disaster Management Authority (DDMA) said.

Those exempted from the curfew include government officials, judges and judicial officers, medical personnel, pregnant women and patients, people going on feet to buy essential items, media persons, and people going to or returning from railway stations, bus stops and airports.

Only exempted-category people will be allowed in Metro trains and public transport buses during the night curfew hours, the DDMA order stated.

Delhi recorded 290 COVID-19 cases on Sunday with a positivity rate of 0.55 per cent. As per the Graded Response Action Plan (GRAP), a 'yellow' alert is sounded if the positivity rate stays at 0.5 per cent on two consecutive days.

A number of restrictions, including night curfew, closure of schools and colleges, halved seating capacity in Metro trains and buses, closure of non-essential shops and malls among others, kick in with the 'yellow alert.



Comments

Post a Comment

Popular posts from this blog

Govt panel recommends EUA for Covovax, Corbevax, Covid pill molnupiravir

Image
An expert panel of the country's central drug authority has recommended granting emergency use authorisation to SII's Covid-19 vaccine Covovax and Biological E's vaccine Corbevax An expert panel of the country's central drug authority has recommended granting emergency use authorisation to Serum Institute of India's COVID-19 vaccine Covovax and Biological E's vaccine Corbevax with certain conditions, official sources said on Monday. The Subject Expert Committee (SEC) on COVID-19 of the Central Drugs Standard Control Organisation (CDSCO) on Monday also recommended granting permission to manufacture and market anti-Covid pill Molnupiravir for restricted emergency use for treatment of adult patients with SpO2 93 per cent and who have high risk of progression of the disease, including hospitalisation or death, subject to certain conditions. All the recommendations have been sent to the Drugs Controller General of India (DCGI) for final approval. The SEC on COVID-19
Read more

Karnataka to jab 310,000 in 15-18 age group, 1.2 mn elders from Jan 3

Image
The Karnataka government has identified 31 lakh beneficiaries in the 15 to 18 age group for the first dose of vaccination and 12 lakh elderly people above the age of 60 years The Karnataka government has identified 31 lakh beneficiaries in the 15 to 18 age group for the first dose of vaccination and 12 lakh elderly people above the age of 60 years with comorbidities across the state for a booster dose. Sources in the health department stated that till date, the state government has vaccinated 76 per cent of the targeted population against Covid. Though jabbing 100 per cent beneficiaries still remains a top priority, the vaccination drive for 15 to 18 years will also be focused as this age segment has not received a single shot of Covid vaccine. The initiative will be taken with missionary zeal in the wake of fears of the Omicron variant and the third wave of Covid. The health department officials maintained that the number of elders might be more and they will also be covered when the
Read more

SARS-CoV-2 can damage heart blood vessels without infecting them

Image
The SARS-CoV-2 virus may contribute to the damage of small blood vessels in the heart as seen in severely-ill Covid-19 patients, without infecting them, a study shows. The research, published in the journal Clinical Science, indicates blocking antibodies could represent a new treatment to alleviate cardiovascular complications. A multidisciplinary research team led by the University of Bristol, UK, analysed how SARS-CoV-2 interacts with heart cells causing the myocardial damage seen in COVID-19 patients. Until now, it remained unclear whether heart cells are infected by the virus or damaged because of an excess cytotoxic defence response.   This response, also known as the cytokine storm', comes from our immune cells, whereby cytotoxic cells attack and kill the infected cells by releasing proteins, called cytokines. The study also investigated whether heart cells contribute to producing excess cytokines. The team led by Professor Paolo Madeddu exposed human heart pericytes, which a
Read more